CA2830081C - Treatment of solid tumours - Google Patents

Treatment of solid tumours Download PDF

Info

Publication number
CA2830081C
CA2830081C CA2830081A CA2830081A CA2830081C CA 2830081 C CA2830081 C CA 2830081C CA 2830081 A CA2830081 A CA 2830081A CA 2830081 A CA2830081 A CA 2830081A CA 2830081 C CA2830081 C CA 2830081C
Authority
CA
Canada
Prior art keywords
cells
methyl
autophagy
mcs
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2830081A
Other languages
English (en)
French (fr)
Other versions
CA2830081A1 (en
Inventor
Stig Linder
Marten Fryknas
Rolf Larsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivolux AB
Original Assignee
Vivolux AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivolux AB filed Critical Vivolux AB
Publication of CA2830081A1 publication Critical patent/CA2830081A1/en
Application granted granted Critical
Publication of CA2830081C publication Critical patent/CA2830081C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2830081A 2011-03-21 2012-03-14 Treatment of solid tumours Active CA2830081C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1100201 2011-03-21
SE1100201-1 2011-03-21
PCT/SE2012/000034 WO2012128689A1 (en) 2011-03-21 2012-03-14 Treatment of solid tumours

Publications (2)

Publication Number Publication Date
CA2830081A1 CA2830081A1 (en) 2012-09-27
CA2830081C true CA2830081C (en) 2020-09-22

Family

ID=46879602

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2830081A Active CA2830081C (en) 2011-03-21 2012-03-14 Treatment of solid tumours

Country Status (20)

Country Link
US (2) US20140073645A1 (enExample)
EP (1) EP2688569B1 (enExample)
JP (1) JP6064215B2 (enExample)
KR (1) KR101937279B1 (enExample)
CN (1) CN103547268B (enExample)
AU (1) AU2012231814B2 (enExample)
BR (1) BR112013024211B1 (enExample)
CA (1) CA2830081C (enExample)
DK (1) DK2688569T3 (enExample)
EA (1) EA025180B1 (enExample)
ES (1) ES2681703T3 (enExample)
HU (1) HUE039021T2 (enExample)
IL (1) IL228411A (enExample)
MX (1) MX2013010770A (enExample)
PL (1) PL2688569T3 (enExample)
PT (1) PT2688569T (enExample)
SG (2) SG193494A1 (enExample)
TR (1) TR201809040T4 (enExample)
WO (1) WO2012128689A1 (enExample)
ZA (1) ZA201307036B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2900667B1 (en) * 2012-09-21 2019-06-05 Vivolux AB Means and method for treating solid tumours
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
CN105807976B (zh) 2014-12-31 2019-02-12 清华大学 静电传感器
KR20180006916A (ko) * 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
CN104997777A (zh) * 2015-07-24 2015-10-28 孔小乐 去铁酮的2比1锌络合物作为制备抗癌药物的应用
JP7103745B2 (ja) * 2015-10-05 2022-07-20 国立大学法人 岡山大学 癌幹細胞抑制剤、癌の転移又は再発の抑制剤並びに癌細胞の未分化マーカー発現抑制剤
PT3390403T (pt) * 2015-12-18 2022-09-06 Vivolux Ab Composição farmacêutica compreendendo derivados de indole, processo para preparação e uso dos mesmos
WO2018119207A1 (en) * 2016-12-21 2018-06-28 The Medical College Of Wisconsin, Inc. Synergistic inihibition of tumor cell proliferation induced by combined treatment of metformin compounds and iron chelators
WO2018147612A1 (ko) * 2017-02-07 2018-08-16 주식회사 온코크로스 암의 전이 억제 및 치료용 조성물
KR101859922B1 (ko) * 2017-02-07 2018-05-21 주식회사 온코크로스 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물
CN106831776B (zh) * 2017-03-16 2018-12-07 河北科技大学 5,10-二氢吡啶并吡嗪并三嗪类化合物及其应用
EP3713573A1 (en) * 2017-11-23 2020-09-30 Deutsches Krebsforschungszentrum Iron chelators in tumor therapy
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN110585194A (zh) * 2019-10-12 2019-12-20 广州医科大学附属第五医院 倍半萜内酯类化合物在制备溶酶体自噬抑制剂以及抗癌药物中的应用
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
CN111849873A (zh) * 2020-07-30 2020-10-30 扬州大学 一种诱导鸡的胚胎干细胞自噬的方法
WO2025263876A1 (ko) 2024-06-17 2025-12-26 서울대학교산학협력단 Vlx600을 포함하는 항균 또는 항진균용 조성물 및 세균 또는 진균 감염증의 예방 또는 치료용 약학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233101A1 (fr) * 1986-01-13 1987-08-19 Ire-Celltarg S.A. Dérivés de vinblastine et composition pharmaceutique les contenant
US5480906A (en) * 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
EP1608623B1 (en) * 2003-02-05 2011-01-19 Desi Raymond Richardson Metal ion chelators and therapeutic use thereof
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
EP1819334A1 (en) * 2004-11-19 2007-08-22 Shiva Biomedical, LLC Methods of treating erythropoietin-resistance
JP2009536180A (ja) * 2006-05-09 2009-10-08 ノバルティス アクチエンゲゼルシャフト 鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
EP2900667B1 (en) 2012-09-21 2019-06-05 Vivolux AB Means and method for treating solid tumours

Also Published As

Publication number Publication date
PL2688569T3 (pl) 2018-09-28
JP6064215B2 (ja) 2017-02-01
US20170348317A1 (en) 2017-12-07
CN103547268A (zh) 2014-01-29
DK2688569T3 (en) 2018-08-06
EA025180B1 (ru) 2016-11-30
AU2012231814A1 (en) 2013-09-26
SG10201605083SA (en) 2016-08-30
ZA201307036B (en) 2014-05-28
KR20140017619A (ko) 2014-02-11
IL228411A0 (en) 2013-12-31
EP2688569A4 (en) 2014-09-10
EP2688569B1 (en) 2018-05-30
IL228411A (en) 2016-12-29
EP2688569A1 (en) 2014-01-29
BR112013024211B1 (pt) 2020-12-15
ES2681703T3 (es) 2018-09-14
KR101937279B1 (ko) 2019-01-10
MX2013010770A (es) 2014-03-27
EA201391286A1 (ru) 2014-03-31
CA2830081A1 (en) 2012-09-27
CN103547268B (zh) 2017-02-22
US20140073645A1 (en) 2014-03-13
AU2012231814B2 (en) 2016-06-09
HUE039021T2 (hu) 2018-12-28
PT2688569T (pt) 2018-08-06
SG193494A1 (en) 2013-10-30
US10022380B2 (en) 2018-07-17
BR112013024211A2 (pt) 2016-12-20
JP2014508804A (ja) 2014-04-10
TR201809040T4 (tr) 2018-07-23
WO2012128689A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
US10022380B2 (en) Treatment of solid tumours
Pei et al. 6-Shogaol from ginger shows anti-tumor effect in cervical carcinoma via PI3K/Akt/mTOR pathway
Sun et al. Magnoflorine inhibits human gastric cancer progression by inducing autophagy, apoptosis and cell cycle arrest by JNK activation regulated by ROS
Milligan et al. The green tea polyphenol EGCG potentiates the Antiproliferative activity of c-met and epidermal growth factor receptor inhibitors in non–small cell lung cancer cells
Harhaji‐Trajkovic et al. AMPK‐mediated autophagy inhibits apoptosis in cisplatin‐treated tumour cells
Li et al. A novel HDAC6 inhibitor Tubastatin A: Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses Temozolomide-induced ER stress-tolerance in GBM cells
Law et al. Hernandezine, a novel AMPK activator induces autophagic cell death in drug-resistant cancers
Syam et al. β Mangostin suppress LPS-induced inflammatory response in RAW 264.7 macrophages in vitro and carrageenan-induced peritonitis in vivo
Li et al. Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells
Su et al. Blocking Parkin/PINK1-mediated mitophagy sensitizes hepatocellular carcinoma cells to sanguinarine-induced mitochondrial apoptosis
CN112870361A (zh) 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用
Mei et al. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin
Baran et al. Novel insights into the antiproliferative effects and synergism of quercetin and menadione in human leukemia Jurkat T cells
Wu et al. Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy
KR20200045845A (ko) N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2015115310A1 (ja) がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤
Yan et al. The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis
Beberok et al. The role of MITF and Mcl-1 proteins in the antiproliferative and proapoptotic effect of ciprofloxacin in amelanotic melanoma cells: In silico and in vitro study
Liu et al. Maackiain dampens osteoclastogenesis via attenuating RANKL‐stimulated NF‐κB signalling pathway and NFATc1 activity
Arafa et al. Sulfadiazine analogs: anti-Toxoplasma in vitro study of s ulfonamide triazoles
Gonzaga et al. A novel triazole derivative drug presenting in vitro and in vivo anticancer properties
Liu et al. New 1, 1-diarylethylene FOXM1 inhibitors potently reduce intracellular FOXM1 and suppress high-grade serous ovarian carcinoma cell viability
HK1191561A (en) Treatment of solid tumours
HK1191561B (en) Treatment of solid tumours
Yang et al. ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170215

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250225

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250225

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260224